Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Core Insights - Corvus Pharmaceuticals announced interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing a favorable safety and efficacy profile [1][2][4] - The company reported cash proceeds of approximately $12.7 million from the early exercise of common stock warrants [1][18] Clinical Trial Overview - The Phase 1 trial is randomized, double-blind, and placebo-controlled, enrolling 64 patients who have previously failed one prior therapy [2][4] - Patients are assigned to one of four dosing cohorts, with doses including 100 mg twice daily, 200 mg once daily, 200 mg twice daily, and 400 mg once daily [2][3] Efficacy Results - In Cohort 1, the mean EASI score reduction at 28 days was 55.9% for soquelitinib compared to 27.0% for placebo, and at 58 days, it was 69.1% for soquelitinib versus 19.1% for placebo [9][10] - At day 28, 75% of soquelitinib patients achieved EASI 50, while no placebo patients achieved EASI 75 or EASI 90 [9][10] - The treatment effect began early, with improvements noted as soon as eight days into the treatment [9] Safety Profile - No significant safety issues were reported, with only two patients in the soquelitinib group experiencing mild adverse events [13][15] - All patients completed the 28-day dosing period without serious adverse events [13][15] Cytokine Analysis - The trial observed reductions in cytokines IL-5, IL-17, IL-31, IL-33, and TSLP, correlating with clinical improvement in EASI scores [16] - No such relationships were observed in the placebo group, indicating a potential mechanism of action for soquelitinib [16] Ongoing Development - The company is looking forward to completing the Phase 1 trial and initiating further trials for soquelitinib in other immune diseases [2][4] - Initial results from Cohort 2, which includes patients receiving 200 mg once daily, are consistent with those from Cohort 1, with no significant adverse events reported [17] Company Background - Corvus Pharmaceuticals is focused on developing ITK inhibition as a novel approach to treat various cancers and immune diseases, with soquelitinib as its lead candidate [23]